[144] Kymera Therapeutics, Inc. SEC Filing
Rhea-AI Filing Summary
KYMR reported officer/affiliate sales disclosed on Form 144. The excerpt lists multiple sales by Atlas Venture Fund X, L.P., Atlas Venture Opportunity Fund I, L.P. and Bruce Booth between 04/14/2026 and 06/18/2026, showing individual transactions with share counts and cash amounts.
The filings identify the security as Common Stock and note prior private placement issuance on 03/11/2020. The excerpt provides per-transaction share counts (for example, 100,928 shares on 06/18/2026) and corresponding cash amounts, but does not state aggregate proceeds to the issuer.
Positive
- None.
Negative
- None.
Insights
Multiple affiliated holders reported open-market or block disposals over April–June 2026.
The excerpt lists discrete sales by Atlas Venture Fund X, L.P., Atlas Venture Opportunity Fund I, L.P. and an individual, Bruce Booth, with dates, share counts, and dollar values. Each line shows the security as Common and indicates cash consideration for the transactions.
These are routine sale disclosures on Form 144; cash‑flow recipients are the selling holders. Timing and aggregated totals across holders are not provided in the excerpt; subsequent filings may show aggregate schedules.